GO:0016595 glutamate binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016595 (glutamate binding) is a molecular function defined as binding to glutamate, the anion of 2-aminopentanedioic acid.
• Glutamate binding is mediated by ionotropic and metabotropic glutamate receptors and by transport or sequestration systems that recognize L-glutamate with high affinity [1,5].
• Hippocampal synaptic membranes contain at least two glutamate binding sites that can be discriminated by their differing affinities for quisqualate.
• At NMDA receptors, glutamate binding is functionally coupled to a separate glycine binding site, and occupancy of both sites is required for efficient receptor activation.
• Glutamate binding is not limited to receptors: a chloride-dependent, L-phenylalanyl-L-glutamate-stimulated binding activity reflects glutamate sequestration mediated by an exchange system.
• Loss of glutamatergic innervation reduces glutamate binding in the rat dorsal vagal complex, showing that binding sites are regulated by neuronal input.
Description
Glutamate binding, annotated as GO:0016595, is the molecular function of selectively and non-covalently interacting with glutamate, the anion of 2-aminopentanedioic acid. In the nervous system, this function is best known as the first step in fast excitatory neurotransmission, where glutamate receptors convert a chemical signal into a cellular response [1,4]. Biochemical studies using radiolabeled L-glutamate have shown that this binding is saturable, stereoselective, and heterogeneous, with distinct sites detectable in insect and mammalian nervous tissue. For example, L-[3H]glutamate binding to hippocampal synaptic membranes resolves into two binding sites that differ in their affinity for quisqualate, indicating that multiple recognition sites coexist in the same membrane preparation. Glutamate binding is therefore not a single uniform event but a family of related molecular interactions with different affinities, pharmacology, and downstream consequences [1,4,8]. Researchers study GO:0016595 because it sits at the interface between amino acid metabolism, membrane transport, and receptor signaling. Binding can represent productive receptor activation, as at NMDA receptors where glutamate and glycine sites cooperate, or it can represent sequestration and exchange, as shown for chloride-dependent, L-phenylalanyl-L-glutamate-stimulated glutamate binding. The function is also plastic: surgical removal of vagal afferents reduces glutamate binding in the rat dorsal vagal complex, demonstrating that the density or accessibility of binding sites depends on intact neuronal circuitry. Understanding glutamate binding therefore requires combining pharmacological, biochemical, and genetic approaches.
glutamate binding At A Glance
| GO ID | GO:0016595 |
|---|---|
| GO term | glutamate binding |
| Ontology | molecular_function |
| Synonym | glutamic acid binding |
| Definition | Binding to glutamate, the anion of 2-aminopentanedioic acid. |
| Major function | Selective non-covalent recognition of glutamate by receptors, transporters, enzymes, and sequestration systems [1,5,6]. |
| Representative assays | Radioligand binding with L-[3H]glutamate on synaptic membrane preparations [1,8]. |
| Pharmacological heterogeneity | Multiple glutamate binding sites discriminated by quisqualate affinity in hippocampal membranes. |
| Regulation by innervation | Glutamate binding in the dorsal vagal complex is reduced after nodose ganglionectomy. |
What Is GO:0016595?
GO:0016595, glutamate binding, is defined in QuickGO as binding to glutamate, the anion of 2-aminopentanedioic acid. In practical terms, it describes any molecular function in which a protein or molecular complex selectively recognizes and non-covalently holds a glutamate molecule. The synonym glutamic acid binding is also used. This function is distinct from glutamate transport, glutamate metabolism, and glutamate receptor signaling activity, although glutamate binding is often the initial recognition step that enables those processes [1,5,6].
Why Is glutamate binding Important in Cell Biology?
Glutamate binding is important because it is the molecular recognition event that initiates most glutamatergic signaling and also underlies glutamate clearance and sequestration. Pharmacological dissection of glutamate binding sites has been central to classifying glutamate receptor agonists and understanding stereochemical requirements for recognition. At the NMDA receptor, the interplay between the glycine and glutamate binding sites determines how the channel responds to coincident signals, making glutamate binding a key control point in synaptic plasticity. Glutamate binding is also relevant beyond classical neurotransmission: chloride-dependent, L-phenylalanyl-L-glutamate-stimulated glutamate binding represents an exchange-mediated sequestration system, linking binding to amino acid homeostasis. Finally, the observation that glutamate binding decreases after nodose ganglionectomy shows that this function is not static but depends on intact neuronal input, which has implications for interpreting binding data in normal and injured tissue.
• Glutamate binding is the initial recognition step for fast excitatory neurotransmission in the mammalian nervous system.
• Multiple glutamate binding sites with different quisqualate affinities exist in hippocampal synaptic membranes, providing a basis for receptor classification.
• NMDA receptor function depends on coordinated glutamate and glycine binding, making glutamate binding a determinant of coincidence detection.
• Chloride-dependent, L-phenylalanyl-L-glutamate-stimulated glutamate binding reflects an exchange system for glutamate sequestration, linking binding to metabolic handling.
• Glutamate binding is stereochemically selective, as reviewed for glutamate receptor agonists.
• Glutamate binding in the dorsal vagal complex is reduced after nodose ganglionectomy, showing dependence on vagal afferent input.
• Glutamate binding assays are used to compare insect and mammalian nervous tissue, highlighting evolutionary conservation of recognition sites.
• Glutamate can also influence nuclear signaling, as shown by inhibition of a neuronal kappaB-binding factor by glutamate.
• Binding studies provide quantitative affinity and site-density data that complement functional electrophysiology [1,8].
• Altered glutamate binding is a measurable phenotype for testing genetic and pharmacological perturbations in preclinical models [3,5].
Molecular Mechanism of glutamate binding
Recognition and initial contact
In simple terms: A glutamate molecule first docks into a pocket on a protein that is shaped to recognize it.
The first stage of glutamate binding is selective recognition of L-glutamate by a binding pocket. Radioligand studies with L-[3H]glutamate on insect and mammalian membranes demonstrated saturable, specific binding, establishing that dedicated recognition sites exist for this amino acid. Stereochemical analyses of glutamate receptor agonists further showed that the spatial arrangement of the glutamate backbone and its acidic groups is critical for productive recognition. This step is reversible and non-covalent, consistent with the GO:0016595 definition of binding to glutamate, the anion of 2-aminopentanedioic acid.
Site heterogeneity and affinity discrimination
In simple terms: Not all glutamate binding sites are the same; some hold glutamate more tightly and some more loosely.
Glutamate binding is heterogeneous. In hippocampal synaptic membranes, L-[3H]glutamate binding resolves into two binding sites that can be discriminated by their differing affinities for quisqualate. This pharmacological heterogeneity means that a single radioligand can report on multiple populations of sites, and that competition experiments are required to assign binding to a specific recognition site. Comparative studies across species likewise indicate that glutamate binding sites are widespread but not identical in their properties.
Coupling to adjacent sites at NMDA receptors
In simple terms: At some receptors, glutamate binding only works well when a second small molecule is also bound nearby.
At the NMDA receptor, glutamate binding is functionally coupled to a separate glycine binding site. Lester and colleagues showed that interactions between the glycine and glutamate binding sites shape receptor activation, so that glutamate binding cannot be interpreted in isolation from occupancy of the glycine site. This makes NMDA receptors a paradigm for allosteric communication between distinct binding events within one molecular machine.
Binding as sequestration and exchange
In simple terms: Sometimes glutamate binding is not about signaling at all; it is about capturing and moving glutamate around.
Not all glutamate binding reflects receptor activation. Kessler and colleagues described a chloride-dependent, L-phenylalanyl-L-glutamate-stimulated glutamate binding activity that represents glutamate sequestration mediated by an exchange system. This finding broadens the functional interpretation of GO:0016595: binding can serve transport, storage, or metabolic routing rather than signal transduction. Investigators therefore need assay conditions that distinguish receptor binding from exchange-mediated sequestration.
Regulation by neuronal input and downstream signaling
In simple terms: The amount of glutamate binding can go up or down depending on the state of the tissue.
Glutamate binding is regulated by neuronal connectivity. Lewis and colleagues found reduced glutamate binding in the rat dorsal vagal complex after nodose ganglionectomy, indicating that intact vagal afferent input is required to maintain normal levels of binding. In addition, glutamate can act on intracellular signaling, as shown by inhibition of the activity of a neuronal kappaB-binding factor by glutamate. Together these observations indicate that glutamate binding is both a target of circuit-level regulation and a trigger for downstream molecular events [3,7].
Key Genes Involved in GO:0016595 glutamate binding
The following genes and proteins are representative molecular players associated with glutamate binding, including ionotropic and metabotropic receptors, NMDA receptor subunits, and transport or sequestration systems.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRIN1 | Obligatory NMDA receptor subunit contributing to the glutamate binding site | Central to studies of coupled glutamate and glycine binding |
| GRIN2A | NMDA receptor subunit that shapes glutamate affinity and channel properties | Target for site-directed mutagenesis of the glutamate binding pocket |
| GRIN2B | NMDA receptor subunit contributing to glutamate recognition | Relevant to developmental and plasticity studies of glutamate binding |
| GRIA1 | AMPA receptor subunit that binds glutamate | Prototype for quisqualate-sensitive glutamate binding sites |
| GRIA2 | AMPA receptor subunit modulating glutamate binding pharmacology | Used to compare high- and low-affinity glutamate sites |
| GRIK1 | Kainate receptor subunit with glutamate binding capability | Comparator for stereochemical requirements of glutamate recognition |
| GRM1 | Metabotropic glutamate receptor that binds glutamate | Model for non-ionotropic glutamate recognition |
| GRM5 | Metabotropic glutamate receptor with glutamate binding site | Used in agonist pharmacology studies |
| SLC1A1 | Glutamate transporter with substrate recognition site | Relevant to distinguishing binding from sequestration |
| SLC1A2 | Glial glutamate transporter recognizing glutamate | Model for exchange-mediated glutamate handling |
| SLC1A3 | Glutamate transporter with glutamate binding and translocation | Used to study chloride-dependent glutamate binding |
| GAD1 | Glutamate decarboxylase acting on glutamate | Links glutamate binding and metabolism in GABAergic neurons |
| GAD2 | Glutamate decarboxylase isoform acting on glutamate | Relevant to glutamate handling in inhibitory circuits |
| GRIN3A | NMDA receptor subunit with distinct glutamate pharmacology | Used to probe heterogeneity of glutamate binding sites |
| GRM2 | Metabotropic glutamate receptor binding glutamate | Comparator for stereochemical agonist requirements |
| GRM3 | Metabotropic glutamate receptor with glutamate binding pocket | Used in agonist selectivity studies |
| NFKB1 | Neuronal kappaB-binding factor inhibited by glutamate | Links glutamate exposure to nuclear signaling readouts |
How Is glutamate binding Regulated?
Glutamate binding is regulated at several levels. At the receptor level, occupancy of the glycine site allosterically influences glutamate binding and activation at NMDA receptors. At the tissue level, glutamate binding in the dorsal vagal complex decreases after nodose ganglionectomy, showing that intact afferent input maintains normal binding capacity. At the biochemical level, chloride-dependent and L-phenylalanyl-L-glutamate-stimulated binding reflects an exchange system, so the apparent level of glutamate binding depends on ion gradients and exchange substrates. Finally, glutamate exposure can modulate nuclear factors such as a neuronal kappaB-binding factor, providing a downstream regulatory readout of glutamate action.
glutamate binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRIN1 | NMDA receptor dysfunction and altered glutamate/glycine coupling | Point-mutation knock-in of the glutamate binding pocket |
| GRIN2A | Glutamatergic signaling disorders | Knockout and rescue with wild-type or mutant subunit |
| GRIA1 | Excitatory synaptic dysfunction | Knockout with radioligand binding readout |
| SLC1A2 | Glutamate sequestration and excitotoxicity | Overexpression and exchange-uptake assays |
| NFKB1 | Glutamate-linked nuclear signaling | Reporter assays after glutamate exposure |
Glutamate binding in neurological and neurodegenerative research
Because glutamate binding initiates excitatory signaling, altered binding capacity is a candidate mechanism in neurological conditions. The demonstration that glutamate binding in the dorsal vagal complex depends on intact vagal afferents suggests that deafferentation or nerve injury can change glutamatergic recognition sites in brainstem circuits. Pharmacological classification of glutamate receptor agonists, including stereochemical aspects, underpins drug discovery for disorders in which glutamatergic transmission is dysregulated.
NMDA receptor dysfunction and glutamate binding
The functional coupling between glycine and glutamate binding sites at NMDA receptors means that abnormalities in either site can alter receptor behavior. Studies of these interacting sites provide a mechanistic framework for interpreting conditions linked to NMDA receptor hypofunction or hyperfunction, and for designing compounds that act at one site while sparing the other.
Glutamate sequestration and metabolic disease relevance
Chloride-dependent, L-phenylalanyl-L-glutamate-stimulated glutamate binding represents an exchange-mediated sequestration system rather than receptor signaling. This distinction matters clinically because it implies that some glutamate binding abnormalities may reflect transport or metabolic dysfunction rather than synaptic receptor changes. Assays that separate these components are therefore important for correct interpretation.
Glutamate signaling to nuclear factors
Glutamate can inhibit the activity of a neuronal kappaB-binding factor, linking glutamate exposure to transcriptional regulation. This observation broadens the disease relevance of glutamate binding beyond ion channels, suggesting that glutamate-dependent nuclear signaling may contribute to cellular stress and inflammatory responses in the nervous system.
From glutamate binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene encode a bona fide glutamate binding protein? | Knockout cell line with L-[3H]glutamate binding assay |
| Which residue determines glutamate affinity? | Point-mutation knock-in of the predicted binding pocket |
| Can a disease-associated variant alter glutamate binding? | Knock-in of the variant with binding and competition assays |
| Where is the glutamate binding protein localized? | Tagged knock-in with imaging and membrane fractionation |
| Does overexpression change glutamate sequestration? | Overexpression model with chloride-dependent binding readout |
| Does loss of innervation change binding site density? | Lesion or ganglionectomy model with regional binding assays |
How to Study the glutamate binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| L-[3H]glutamate radioligand binding | Affinity and density of glutamate binding sites | Membrane preparations from nervous tissue |
| Competition binding with quisqualate | Discrimination of multiple glutamate binding sites | Hippocampal synaptic membranes |
| Chloride-dependent binding assay | Exchange-mediated glutamate sequestration | Differentiating binding from transport |
| Stereochemical agonist panel | Selectivity of glutamate recognition | Glutamate receptor agonist classification |
| Glycine site interaction assay | Allosteric coupling at NMDA receptors | NMDA receptor mechanism studies |
| Nodose ganglionectomy plus regional binding | Effect of innervation on binding site density | Brainstem circuit studies |
| Reporter assay for kappaB-binding factor | Downstream nuclear response to glutamate | Glutamate signaling studies |
Radioligand binding assays
Direct binding assays with L-[3H]glutamate remain the core method for measuring GO:0016595. They can resolve multiple sites when combined with competitors such as quisqualate, as shown in hippocampal synaptic membranes. Comparative studies in insect and mammalian tissue illustrate how the same assay format can be applied across species.
Pharmacological and stereochemical profiling
Because glutamate recognition is stereochemically selective, agonist panels are used to define the specificity of a binding site. Such profiling helps distinguish receptor binding from sequestration and provides structure-activity information for tool compound development [4,5].
Ion-dependence and exchange assays
Chloride-dependent and L-phenylalanyl-L-glutamate-stimulated binding assays are used to detect exchange-mediated glutamate sequestration. Varying ion composition and substrate availability allows investigators to separate this component from receptor binding.
Lesion and circuit-level studies
Regional binding assays after nodose ganglionectomy demonstrate how surgical or genetic disruption of afferent input changes glutamate binding in the dorsal vagal complex. This approach links circuit integrity to molecular recognition capacity.
How CRISPR Can Be Used to Study GO:0016595 glutamate binding
Knockout
CRISPR knockout of candidate genes followed by L-[3H]glutamate binding assays can test whether a protein is required for a specific glutamate binding site. This approach is grounded in the principle that binding sites can be resolved pharmacologically, so loss of a site after knockout provides causal evidence. Knockout models are also useful for separating receptor binding from exchange-mediated sequestration.
Point Mutation
Point mutations in predicted glutamate-coordinating residues allow precise testing of binding determinants. Because glutamate recognition is stereochemically stringent, even conservative substitutions can alter affinity, and point-mutation models combined with competition binding provide residue-level insight. At NMDA receptors, point mutations can also probe coupling between glutamate and glycine sites.
Knock-in
Knock-in of disease-associated or experimentally designed variants enables study of glutamate binding in a physiological context. Tagged knock-in additionally allows localization of the binding protein relative to synaptic and transport compartments. Knock-in models are particularly valuable when binding changes are expected to be quantitative rather than absolute.
Overexpression
Overexpression of a candidate glutamate binding protein can increase the measurable binding signal and reveal sequestration or exchange activity. This is especially informative for chloride-dependent, L-phenylalanyl-L-glutamate-stimulated binding, where the exchange system can be amplified and studied in isolation. Overexpression combined with pharmacological profiling helps confirm that the observed binding has the expected selectivity.
How EDITGENE Supports glutamate binding Research
Researchers studying glutamate binding-related genes often need to determine whether a candidate gene is causally involved in a specific binding site, whether a particular residue controls affinity, and whether a disease variant changes recognition. Answering these questions requires clean genetic models in which the binding function can be measured against a defined background. EDITGENE provides CRISPR-based cell models and screening services designed to support exactly this kind of mechanistic work on GO:0016595 and related glutamatergic functions.
Contact EDITGENE today to design your custom CRISPR model for glutamate binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GRIN2B Knockout HEK293 Cell Line | EDJ-KQ668 | Human | 2904 | Details Get a Quote |
| GRM7 Knockout HEK293 Cell Line | EDJ-KQ1070 | Human | 2917 | Details Get a Quote |
| GRIN1 Knockout HEK293 Cell Line | EDJ-KQ1219 | Human | 2902 | Details Get a Quote |
| GRIN2D Knockout HEK293 Cell Line | EDJ-KQ1577 | Human | 2906 | Details Get a Quote |
| CPS1 Knockout HEK293 Cell Line | EDJ-KQ1984 | Human | 1373 | Details Get a Quote |
| SLC1A3 Knockout HEK293 Cell Line | EDJ-KQ2547 | Human | 6507 | Details Get a Quote |
| GCLC Knockout HEK293 Cell Line | EDJ-KQ3948 | Human | 2729 | Details Get a Quote |
| CPS1 Knockout A-549 Cell Line | EDJ-KQ21962 | Human | 1373 | Details Get a Quote |
| CPS1 Knockout HCT 116 Cell Line | EDJ-KQ21963 | Human | 1373 | Details Get a Quote |
| CPS1 Knockout HeLa Cell Line | EDJ-KQ21964 | Human | 1373 | Details Get a Quote |
| GRIN2D Knockout A-549 Cell Line | EDJ-KQ19907 | Human | 2906 | Details Get a Quote |
| GRIN1 Knockout HCT 116 Cell Line | EDJ-KQ20548 | Human | 2902 | Details Get a Quote |
| GRIN2B Knockout A-549 Cell Line | EDJ-KQ20549 | Human | 2904 | Details Get a Quote |
| GRIN2B Knockout HCT 116 Cell Line | EDJ-KQ20550 | Human | 2904 | Details Get a Quote |
| GRIN2D Knockout HCT 116 Cell Line | EDJ-KQ21263 | Human | 2906 | Details Get a Quote |
Displaying Records 1 To 15 Of 29 Records
Frequently Asked Questions About glutamate binding
What is GO:0016595?
GO:0016595 is the Gene Ontology molecular function term for glutamate binding, defined as binding to glutamate, the anion of 2-aminopentanedioic acid, with the synonym glutamic acid binding.
What is glutamate binding?
Glutamate binding is the selective, non-covalent recognition of glutamate by a protein or molecular complex, and it can serve receptor signaling, transport, or sequestration [1,5].
What genes are involved in glutamate binding?
Genes encoding ionotropic and metabotropic glutamate receptors, NMDA receptor subunits, and glutamate transporters are involved, including GRIN1, GRIN2A, GRIN2B, GRIA1, GRIA2, GRIK1, GRM1, GRM5, SLC1A1, SLC1A2, and SLC1A3 [4,5,6,8].
How is glutamate binding measured experimentally?
It is commonly measured by radioligand binding with L-[3H]glutamate on membrane preparations, often combined with competitors such as quisqualate to resolve multiple sites [1,8].
Are there multiple glutamate binding sites?
Yes. In hippocampal synaptic membranes, L-[3H]glutamate binding resolves into two sites that differ in their affinity for quisqualate.
How does glycine affect glutamate binding at NMDA receptors?
The glycine and glutamate binding sites of the NMDA receptor interact functionally, so glutamate binding is coupled to glycine site occupancy.
Can glutamate binding occur without receptor signaling?
Yes. Chloride-dependent, L-phenylalanyl-L-glutamate-stimulated glutamate binding represents glutamate sequestration mediated by an exchange system rather than receptor activation.
Does nerve injury change glutamate binding?
Yes. Glutamate binding in the rat dorsal vagal complex is reduced after nodose ganglionectomy, indicating dependence on intact vagal afferent input.
Does glutamate affect nuclear signaling?
Glutamate can inhibit the activity of a neuronal kappaB-binding factor, linking glutamate exposure to nuclear regulatory events.
How can CRISPR help study glutamate binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes and residues in glutamate binding assays [4,5,6,8].
Conclusion
GO:0016595 glutamate binding captures a fundamental molecular recognition event that underlies glutamatergic signaling, glutamate sequestration, and downstream nuclear responses. Biochemical and pharmacological studies have established that glutamate binding is saturable, stereoselective, and heterogeneous, with multiple sites distinguishable by quisqualate affinity and by coupling to glycine sites at NMDA receptors [1,4,6,8]. The function is also dynamic, as shown by reduced binding after nodose ganglionectomy. CRISPR-based models now make it possible to test causality for candidate genes and residues, and to separate receptor binding from exchange-mediated sequestration. Together, these approaches position glutamate binding as a tractable and clinically relevant target for mechanistic research.
References
- 1. Briley PA et al.. 1981. Glutamate receptor binding in insects and mammals.. Mol Cell Biochem 39:347-56 PMID: 6118825
- 3. Lewis SJ et al.. 1988. Reduced glutamate binding in rat dorsal vagal complex after nodose ganglionectomy.. Brain Res Bull 21(6):913-6 PMID: 2906272
- 4. Vogensen SB et al.. 2011. Glutamate receptor agonists: stereochemical aspects.. Curr Top Med Chem 11(7):887-906 PMID: 21291400
- 5. Kessler M et al.. 1987. L-phenylalanyl-L-glutamate-stimulated, chloride-dependent glutamate binding represents glutamate sequestration mediated by an exchange system.. J Neurochem 48(4):1191-200 PMID: 2880930
- 6. Lester RA et al.. 1993. Interactions between the glycine and glutamate binding sites of the NMDA receptor.. J Neurosci 13(3):1088-96 PMID: 8095067
- 7. Mao X et al.. 1999. Inhibition of the activity of a neuronal kappaB-binding factor by glutamate.. J Neurochem 73(5):1851-8 PMID: 10537043
- 8. Werling LL et al.. 1983. L-[3H]Glutamate binding to hippocampal synaptic membranes: two binding sites discriminated by their differing affinities for quisqualate.. J Neurochem 41(2):586-93 PMID: 6135754
